Virtus ETF Advisers LLC Syros Pharmaceuticals, Inc. Transaction History

Virtus ETF Advisers LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$3.26 - $4.66 $117,663 - $168,193	-36,093 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$4.08 - $5.66 $7,686 - $10,663	-1,884 Reduced 4.96%	36,093 $161,000
Q2 2021 Aug 10, 2021	BUY	$5.01 - $7.48 $61,142 - $91,285	12,204 Added 47.35%	37,977 $207,000
Q1 2021 May 17, 2021	BUY	$7.19 - $14.95 $3,235 - $6,727	450 Added 1.78%	25,773 $193,000
Q4 2020 Feb 12, 2021	SELL	$6.66 - $14.66 $63,349 - $139,445	-9,512 Reduced 27.31%	25,323 $275,000
Q3 2020 Nov 13, 2020	SELL	$8.69 - $14.47 $41,216 - $68,631	-4,743 Reduced 11.98%	34,835 $308,000
Q2 2020 Aug 05, 2020	BUY	$5.21 - $11.03 $206,201 - $436,545	39,578 New	39,578 $422,000
Q4 2018 Feb 05, 2019	SELL	$5.55 - $11.34 $197,585 - $403,715	-35,601 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$9.74 - $12.92 $254,389 - $337,444	-26,118 Reduced 42.32%	35,601 $424,000
Q2 2018 Aug 10, 2018	BUY	$10.16 - $13.65 $627,065 - $842,464	61,719 New	61,719 $630,000

Ticker SYRS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 20,236,200
Market Cap $5.87M
Description
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically def...

Get notified when there are updates to the investment portfolio of Virtus ETF Advisers LLC, based on Form 13F filings with the SEC.

Stay updated on Virtus ETF Advisers LLC with notifications on news.